PHARMA.AI is the only generative AI-powered drug discovery and development platform that provides end-to-end drug discovery and development services. The platform consists of three components: PandaOmics (for target discovery), Chemistry42 (for molecular synthesis) and inClinico (for clinical trial prediction and optimization). The platform was also used to develop Insilico's internal pipeline of 31 programs across 29 drug targets, including one clinical-stage drug candidate, ISM001-055, for IPF.